

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Ellison Mark Jason Heath</u> <hr/> (Last) (First) (Middle) 201 SANTA MONICA BLVD <hr/> (Street) SANTA MONICA CA 90401 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 07/09/2019	3. Issuer Name and Ticker or Trading Symbol <u>OPIANT PHARMACEUTICALS, INC. [OPNT]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) <u>UK Managing Director</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) <hr/> 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiration Date					
Common Stock	08/02/2014 ⁽¹⁾	08/01/2019	Common Stock	30,000	10	I	See footnote (2) ⁽²⁾
Common Stock	01/02/2015 ⁽¹⁾	01/24/2020	Common Stock	10,000	10	I	See footnote (2)
Common Stock	02/13/2019 ⁽³⁾	02/12/2028	Common Stock	100,000	24.79	D	
Common Stock	02/03/2019 ⁽⁴⁾	01/02/2029	Common Stock	7,200	13.61	D	

Explanation of Responses:

- All of the shares subject to this option are fully vested and exercisable as of the date hereof.
- The option is held by Phax Limited, of which the Reporting person serves as the Director.
- One-fourth of the shares subject to the option vested on February 13, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
- One forty-eighth of the shares subject to the option vested on February 3, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as service provider through each such date.

Remarks:

/s/ Mark Jason Heath Ellison 07/11/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.